Cell therapy

Knee x-ray
#Cell therapy #Osteoarthritis #Phase I trial #Scarcell Therapeutics

First-ever use of donor gum cells to treat osteoarthritis

Scarcell Therapeutics has treated the first patients with its allogenic gingival fibroblast (aGF) therapy using gum cells from a human donor as part of its Phase Ib clinical trial studying the therapy in knee osteoarthritis (OA).   The first-in-human cases took place at Oxford University Hospitals, UK, and… Read More

#News

Cell therapy platform
#Cell therapy #Cellular Origins #Financing

Cellular Origins complete $40 million financing round  

TTP company Cellular Origins has completed a $40 million Series A financing round to accelerate its development of scalable cell therapy manufacture.  The Series A financing was led by Johnson & Johnson, through its corporate venture capital organisation, Johnson & Johnson Innovation, with the syndicate comprising Highland Europe, BGF, NYBC Ventures, and… Read More

#Business & Investment #News

#Advanced Therapies #Cancer research #Cell therapy #Pancreatic cancer

Tumour-regressing cell therapy advanced towards clinic 

Drug discovery company Lunai Bioworks has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, advancing the treatment to clinic.  Lunai’s Dendritic Cell Combination Therapy (DCCT) achieved complete regression of both primary and metastatic pancreatic tumours with no recurrence in humanised pre-clinical models. Read More

#Cancer Research #News

T cell therapy in lupus
#Biotech #Business #Cell therapy

Cue Biopharma and ImmunoScape partner on cell therapies 

Biotechnology companies Cue Biopharma and ImmunoScape have entered into a collaboration and license agreement to advance cell therapies for the treatment of solid tumours.  Under the agreement, ImmunoScape will develop a novel ‘Seed-and-Boost’ immunotherapy that combines Cue Biopharma’s clinically-validated Immuno-STAT T-cell engagers with ImmunoScape’s proprietary TCRs. The combination therapy is designed to overcome core limitations of existing cell therapies with the potential… Read More

#Business & Investment #News

T cells
#CAR-T #Cell therapy #Drug discovery #Webinar

Watch now: Technology & techniques to advance T cell therapy

Accelerate your CAR-T research. Watch this on-demand webinar ‘Next-generation tools for CAR-T and T cell therapy research’ to discover high-throughput imaging innovations for assessing cytotoxicity, T cell activation, and proliferation across 2D/3D models. Get proven methods and actionable insights to optimise constructs and scale up your translational assays. You… Read More

Webinar date:
Brought to you by Agilent
#News

T cells
#CAR-T #Cell therapy #Drug discovery #Webinar

Technology & techniques to advance your T cell therapy

Accelerate your CAR-T research. Discover high-throughput imaging innovations for assessing cytotoxicity, T cell activation, and proliferation across 2D/3D models. Get proven methods and actionable insights to optimise constructs and scale up your translational assays. You will learn: Ways to evaluate immune cell behavior and function Practical strategies for optimising your… Read More

Webinar date:
Brought to you by Agilent
#Webinars

CAR-T therapy
#Autoimmune disease #Bristol Myers Squibb #CAR-T #Cell therapy #Lupus

BMS’s CAR-T shows potential for immune reset in lupus

Bristol Myers Squibb has shared its first results in chronic, refractory autoimmune diseases from the Phase I Breakfree-1 study of its investigational, autologous CD19-targeted NEX-T CAR T cell therapy BMS-986353 (CC-97540).   The data evaluates a total of 71 treated patients across the systemic sclerosis (SSc), systemic lupus… Read More

#Editor's Choice #News

#Artificial intelligence (AI) #AstraZeneca #Business #Cell therapy #Google #Immunotherapy

DDW Highlights: 28 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, Galapagos announced plans to shelve its cell therapy business and hundreds of… Read More

#Podcasts

#Artificial intelligence (AI) #AstraZeneca #Business #Cell therapy #DDW Turning Science into Business Symposium #Google #Immunotherapy

This week in Drug Discovery (20 – 24 October)

News round-up for 20 – 24 October by Bruno Quinney, Content Team at DDW.  This week’s leading story comes from biotech, with Galapagos announcing plans to shelve its cell therapy business and hundreds of employees set to lose theirjobs. Elsewhere, pharma firms are offering discounts to US… Read More

#News

#Cell therapy #Galapagos

Galapagos plans to end cell therapy efforts and close sites

Galapagos has announced its intention to wind down its cell therapy business, following a comprehensive review of strategic alternatives, including a potential divestiture.  The move follows similar ones by Novo Nordisk and Takeda, which recently announced the decision to discontinue its cell therapy efforts, as part of a “strategic portfolio… Read More

#Business & Investment #News #Trending News

CAR T-cells attacking a cancer cell
#Bristol Myers Squibb #CAR-T #Cell therapy #In vivo #Mergers and acquisitions

BMS boosts cell therapy portfolio with Orbital acquisition

Bristol Myers Squibb has announced plans to acquire in vivo CAR-T company Orbital Therapeutics for $1.5 billion.  The acquisition includes Orbital’s lead RNA immunotherapy preclinical candidate currently in IND-enabling studies, OTX-201, which comprises an optimised circular RNA encoding a CD19-targeted CAR for in vivo expression delivered via targeted lipid nanoparticles… Read More

#Business & Investment #News

Human cell
#AI / data analytics / healthtech / informatics #bit bio #CAR-T #Cell therapy #Data security #Stem cells

New podcast: Overcoming barriers to patient access

This is the latest episode of the free DDW narrated podcast, titled “Overcoming barriers to patient access”, which covers two articles written for DDW Volume 25 – Issue 1, Winter 2023/24. They are called: “Scaling up: The need for human cells to give better access to cell therapies” and… Read More

#News

CAR-T cell therapy
#Autoimmune disease #CAR-T #Cell therapy #Immunotherapy #Ulcerative colitis (UC)

First use of CAR-T therapy to treat ulcerative colitis

A team of physicians at the German Center for Immunotherapy at Erlangen University Hospital has succeeded for the first time worldwide in treating a 21-year-old female patient with therapy-resistant, severe chronic inflammatory bowel disease (ulcerative colitis) using cell therapy with CD19 CAR-T cells.  The 21-year-old patient had… Read More

#Editor's Choice #News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Webinar: The latest advances in advanced therapies discovery

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this free webinar on 25 September will explore developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Healthy cells
#CAR-T #Cell therapy #FDA #United States

FDA cracks down on overseas cell processing for clinical trials

The US Food and Drug Administration (FDA) has prohibited new clinical trials that send US patients’ live cells overseas, including to China, for gene editing and return infusion.   While the scope and impact are unclear, smaller cell and gene therapy companies that rely on foreign manufacturing may… Read More

#News